Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn's Disease
Laurent Peyrin-Biroulet, Edouard Louis, Edward V Loftus Jr, Ana Lacerda, Qian Zhou, Yuri Sanchez Gonzalez, Subrata Ghosh, Laurent Peyrin-Biroulet, Edouard Louis, Edward V Loftus Jr, Ana Lacerda, Qian Zhou, Yuri Sanchez Gonzalez, Subrata Ghosh
Abstract
Introduction: In the phase 2 CELEST study, positive efficacy results were obtained with the Janus kinase 1 inhibitor upadacitinib for adult patients with moderate to severe Crohn's disease. We present the health-related quality of life and work productivity improvement results with upadacitinib from CELEST.
Methods: CELEST (NCT02365649) was a double-blind study where patients were randomized 1:1:1:1:1:1 in the 16-week induction period to placebo or upadacitinib 3 mg twice daily (BID), 6 mg BID, 12 mg BID, 24 mg BID, or 24 mg once daily (QD). Patients completing the induction period were re-randomized 1:1:1 to receive upadacitinib 3 mg BID, 12 mg BID, or 24 mg QD for 36 weeks or 3 mg BID, 6 mg BID, or 12 mg BID (after amendment). Inflammatory Bowel Disease Questionnaire (IBDQ), European Quality of Life-5 Dimensions visual analog scale (EQ-5D VAS), and Work Productivity and Activity Impairment (WPAI) questionnaire outcomes were assessed at baseline and Weeks 8, 16, and 52.
Results: At Week 16, a significant percentage (P ≤ 0.05) of patients receiving upadacitinib 6-mg BID dose or higher achieved IBDQ response (IBDQ score change ≥ 16 points; 49%-57% for upadacitinib vs. 24% for placebo) and IBDQ remission, except 24 mg QD (IBDQ score ≥ 170; 26%-39% for upadacitinib vs. 11% for placebo). Greater improvements in IBDQ total score, EQ-5D VAS, and activity impairment from baseline (P ≤ 0.1) versus placebo were also observed. Larger improvements (P ≤ 0.1) in IBDQ response and total score and EQ-5D VAS were observed at Week 8 with 6 and 24 mg BID versus placebo, with improvements for all dosages maintained or greater at Week 52 for IBDQ, EQ-5D VAS, and WPAI endpoints, in particular for the 12-mg BID group.
Conclusion: Improvements in health-related quality of life and work productivity were achieved and sustained with upadacitinib in patients with moderate to severe Crohn's disease.
Trial registration: ClinicalTrials.gov identifier, NCT02365649.
Keywords: CELEST; European Quality of Life-5 Dimensions Visual Analog Scale; Inflammatory Bowel Disease Questionnaire; Janus kinase 1; Quality of life; Upadacitinib; Work Productivity and Activity Impairment Questionnaire.
Figures
References
- Roda G, Chien Ng S, Kotze PG, et al. Crohn's disease. Nat Rev Dis Prim. 2020;6:22. doi: 10.1038/s41572-020-0156-2.
- Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn's disease in adults. Am J Gastroenterol. 2018;113:481–517. doi: 10.1038/ajg.2018.27.
- Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389:1741–1755. doi: 10.1016/S0140-6736(16)31711-1.
- Gomollon F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3–25. doi: 10.1093/ecco-jcc/jjw168.
- Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390:2769–2778. doi: 10.1016/S0140-6736(17)32448-0.
- Wilburn J, McKenna SP, Twiss J, Kemp K, Campbell S. Assessing quality of life in Crohn's disease: development and validation of the Crohn's Life Impact Questionnaire (CLIQ) Qual Life Res. 2015;24:2279–2288. doi: 10.1007/s11136-015-0947-1.
- Vergara M, Montserrat A, Casellas F, et al. A new validation of the Spanish Work Productivity and Activity Impairment Questionnaire-Crohn's disease version. Value Health. 2011;14:859–861. doi: 10.1016/j.jval.2011.02.1179.
- Gower-Rousseau C, Sarter H, Savoye G, et al. Validation of the inflammatory bowel disease disability index in a population-based cohort. Gut. 2017;66:588–596. doi: 10.1136/gutjnl-2015-310151.
- Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011;33:987–995. doi: 10.1111/j.1365-2036.2011.04612.x.
- Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol. 2011;106:674–684. doi: 10.1038/ajg.2011.60.
- Hammaren HM, Virtanen AT, Raivola J, Silvennoinen O. The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine. 2019;118:48–63. doi: 10.1016/j.cyto.2018.03.041.
- Yamamoto-Furusho JK. Inflammatory bowel disease therapy: blockade of cytokines and cytokine signaling pathways. Curr Opin Gastroenterol. 2018;34:187–193. doi: 10.1097/MOG.0000000000000444.
- Cui D, Huang G, Yang D, Huang B, An B. Efficacy and safety of interferon-gamma-targeted therapy in Crohn's disease: a systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol. 2013;37:507–513. doi: 10.1016/j.clinre.2012.12.004.
- Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494) BMC Rheumatol. 2018;2:23. doi: 10.1186/s41927-018-0031-x.
- Sandborn WJ, Feagan BG, Loftus EV, Jr, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease. Gastroenterology. 2020;158:2123–2138. doi: 10.1053/j.gastro.2020.01.047.
- RINVOQ™ (upadacitinib) prescribing information, AbbVie Inc., North Chicago, IL, USA. 2019.
- Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology. 1994;106:287–96.
- Mitchell A, Guyatt G, Singer J, et al. Quality of life in patients with inflammatory bowel disease. J Clin Gastroenterol. 1988;10:306–310. doi: 10.1097/00004836-198806000-00014.
- Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96:804–810. doi: 10.1016/S0016-5085(89)80080-0.
- Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group. Gastroenterology. 1994;106:287–96.
- Abbass M, Cepek J, Parker CE, et al. Adalimumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2019 doi: 10.1002/14651858.CD012878.pub2.
- Gregor JC, McDonald JW, Klar N, et al. An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis. 1997;3:265–276. doi: 10.1097/00054725-199712000-00004.
- Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12(1246–56):e6.
- Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22:1717–1727. doi: 10.1007/s11136-012-0322-4.
- Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353–365. doi: 10.2165/00019053-199304050-00006.
- Reilly MC, Gerlier L, Brabant Y, Brown M. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. Clin Ther. 2008;30:393–404. doi: 10.1016/j.clinthera.2008.02.016.
- Reilly Associates. Work productivity and activity questionnaire specific health problem V2.0 (WPAI-SHP). 2010. . Cited 15 June 2020.
- Khan I, Sarker SJ, Hackshaw A. Smaller sample sizes for phase II trials based on exact tests with actual error rates by trading-off their nominal levels of significance and power. Br J Cancer. 2012;107:1801–1809. doi: 10.1038/bjc.2012.444.
- Sandborn WJ, Reilly MC, Brown CJ, Brabant Y, Gerlier LC. Minimally important difference for WPAI:CD scores: defining relevant impact on work productivity in active Crohn's disease. Am J Gastroenterol. 2007;102:S472. doi: 10.14309/00000434-200709002-00962.
- Byron C, Cornally N, Burton A, Savage E. Challenges of living with and managing inflammatory bowel disease: a meta-synthesis of patients' experiences. J Clin Nurs. 2020;29:305–319. doi: 10.1111/jocn.15080.
- Garcia-Sanjuan S, Lillo-Crespo M, Richart-Martinez M, Sanjuan Quiles A. Understanding life experiences of people affected by Crohn's disease in Spain. A phenomenological approach. Scand J Car Sci. 2018;32:354–62.
- Loftus EV, Feagan BG, Colombel JF, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. 2008;103:3132–3141. doi: 10.1111/j.1572-0241.2008.02175.x.
- Louis E, Lofberg R, Reinisch W, et al. Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial. J Crohns Colitis. 2013;7:34–43. doi: 10.1016/j.crohns.2012.02.017.
- Colombel JF, Reinisch W, Mantzaris GJ, et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease—a SONIC post hoc analysis. Aliment Pharmacol Ther. 2015;41:734–746. doi: 10.1111/apt.13139.
- Vermeire S, Loftus EV, Jr, Colombel JF, et al. Long-term efficacy of vedolizumab for Crohn's disease. J Crohns Colitis. 2017;11:412–424.
- Feagan BG, Sandborn WJ, Wolf DC, et al. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther. 2011;33:541–550. doi: 10.1111/j.1365-2036.2010.04568.x.
- Sands BE, Han C, Gasink C, et al. The effects of ustekinumab on health-related quality of life in patients with moderate to severe Crohn's disease. J Crohns Colitis. 2018;12:883–895. doi: 10.1093/ecco-jcc/jjy055.
Source: PubMed